FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025720477> ?p ?o ?g. }

• W3025720477 endingPage "977" @default.
• W3025720477 startingPage "967" @default.
• W3025720477 abstract "Aims: Pembrolizumab demonstrated significantly prolonged overall survival (OS) vs. chemotherapy in the Phase III KEYNOTE-045 trial, and is approved in the US for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who progressed after platinum-based chemotherapy. Using longer follow-up and individual patient-data from KEYNOTE-045, this study evaluates the cost-effectiveness of pembrolizumab vs. chemotherapy or atezolizumab from a US payer perspective.Materials and methods: A partitioned-survival model was developed over a 20-year time horizon. Progression-free survival (PFS) and OS for pembrolizumab and chemotherapy were extrapolated using a piecewise modelling approach, where patient-level data from KEYNOTE-045 were used for the initial period followed by parametric distributions. OS of atezolizumab was estimated by indirect treatment comparisons based on KEYNOTE-045 and IMvigor211. Different scenarios were explored in the absence of indirect comparisons on PFS and time-on-treatment (ToT) between pembrolizumab and atezolizumab. Drug acquisition/administration, disease management, adverse events, and terminal care costs were considered.Results: Compared with chemotherapy, pembrolizumab resulted in a mean gain of 1.33 life-years and 1.14 quality-adjusted life-years (QALYs) and an incremental cost of $106,299, yielding an incremental cost-effectiveness ratio of $93,481/QALY gained. Pembrolizumab dominated atezolizumab in extending patients’ life by 0.89 years and 0.76 QALYs, while reducing costs by $26,458. Key drivers of cost-effectiveness included survival extrapolation, OS hazard ratio of pembrolizumab vs. atezolizumab, and time horizon. Pembrolizumab had a 66% and 100% probability of being cost-effective vs. chemotherapy and atezolizumab, respectively, at a $100,000 willingness-to-pay threshold.Limitations and conclusions: Uncertainties remain with extrapolated PFS and OS for pembrolizumab, OS indirect comparison, and ToT for atezolizumab. Despite these limitations, the model used robust methods to estimate key clinical endpoints with patient-level data from longer follow-up of KEYNOTE-045. Pembrolizumab dominates atezolizumab and is very likely cost-effective vs. chemotherapy in 2 L mUC at a $100,000 willingness-to-pay threshold." @default.
• W3025720477 created "2020-05-21" @default.
• W3025720477 creator A5004167433 @default.
• W3025720477 creator A5008321836 @default.
• W3025720477 creator A5027096668 @default.
• W3025720477 creator A5032929035 @default.
• W3025720477 creator A5052069729 @default.
• W3025720477 creator A5055266545 @default.
• W3025720477 creator A5055870970 @default.
• W3025720477 creator A5073279585 @default.
• W3025720477 creator A5082742595 @default.
• W3025720477 creator A5085140824 @default.
• W3025720477 date "2020-06-12" @default.
• W3025720477 modified "2023-10-16" @default.
• W3025720477 title "The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States" @default.
• W3025720477 cites W1480519071 @default.
• W3025720477 cites W1858135205 @default.
• W3025720477 cites W1982967337 @default.
• W3025720477 cites W1994192011 @default.
• W3025720477 cites W2022946202 @default.
• W3025720477 cites W2096782143 @default.
• W3025720477 cites W2102116016 @default.
• W3025720477 cites W2137578070 @default.
• W3025720477 cites W2152194109 @default.
• W3025720477 cites W2292562657 @default.
• W3025720477 cites W2588916311 @default.
• W3025720477 cites W2591772299 @default.
• W3025720477 cites W2777192533 @default.
• W3025720477 cites W2792717752 @default.
• W3025720477 cites W2806532569 @default.
• W3025720477 cites W2901496373 @default.
• W3025720477 cites W2905414330 @default.
• W3025720477 cites W2943108118 @default.
• W3025720477 doi "https://doi.org/10.1080/13696998.2020.1770261" @default.
• W3025720477 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32412387" @default.
• W3025720477 hasPublicationYear "2020" @default.
• W3025720477 type Work @default.
• W3025720477 sameAs 3025720477 @default.
• W3025720477 citedByCount "13" @default.
• W3025720477 countsByYear W30257204772020 @default.
• W3025720477 countsByYear W30257204772021 @default.
• W3025720477 countsByYear W30257204772022 @default.
• W3025720477 countsByYear W30257204772023 @default.
• W3025720477 crossrefType "journal-article" @default.
• W3025720477 hasAuthorship W3025720477A5004167433 @default.
• W3025720477 hasAuthorship W3025720477A5008321836 @default.
• W3025720477 hasAuthorship W3025720477A5027096668 @default.
• W3025720477 hasAuthorship W3025720477A5032929035 @default.
• W3025720477 hasAuthorship W3025720477A5052069729 @default.
• W3025720477 hasAuthorship W3025720477A5055266545 @default.
• W3025720477 hasAuthorship W3025720477A5055870970 @default.
• W3025720477 hasAuthorship W3025720477A5073279585 @default.
• W3025720477 hasAuthorship W3025720477A5082742595 @default.
• W3025720477 hasAuthorship W3025720477A5085140824 @default.
• W3025720477 hasBestOaLocation W30257204771 @default.
• W3025720477 hasConcept C112930515 @default.
• W3025720477 hasConcept C121608353 @default.
• W3025720477 hasConcept C126322002 @default.
• W3025720477 hasConcept C143998085 @default.
• W3025720477 hasConcept C2775949291 @default.
• W3025720477 hasConcept C2777701055 @default.
• W3025720477 hasConcept C2780057760 @default.
• W3025720477 hasConcept C2780352672 @default.
• W3025720477 hasConcept C2911057145 @default.
• W3025720477 hasConcept C3019080777 @default.
• W3025720477 hasConcept C3019882237 @default.
• W3025720477 hasConcept C71924100 @default.
• W3025720477 hasConceptScore W3025720477C112930515 @default.
• W3025720477 hasConceptScore W3025720477C121608353 @default.
• W3025720477 hasConceptScore W3025720477C126322002 @default.
• W3025720477 hasConceptScore W3025720477C143998085 @default.
• W3025720477 hasConceptScore W3025720477C2775949291 @default.
• W3025720477 hasConceptScore W3025720477C2777701055 @default.
• W3025720477 hasConceptScore W3025720477C2780057760 @default.
• W3025720477 hasConceptScore W3025720477C2780352672 @default.
• W3025720477 hasConceptScore W3025720477C2911057145 @default.
• W3025720477 hasConceptScore W3025720477C3019080777 @default.
• W3025720477 hasConceptScore W3025720477C3019882237 @default.
• W3025720477 hasConceptScore W3025720477C71924100 @default.
• W3025720477 hasIssue "9" @default.
• W3025720477 hasLocation W30257204771 @default.
• W3025720477 hasOpenAccess W3025720477 @default.
• W3025720477 hasPrimaryLocation W30257204771 @default.
• W3025720477 hasRelatedWork W2626043568 @default.
• W3025720477 hasRelatedWork W2808310746 @default.
• W3025720477 hasRelatedWork W2899953288 @default.
• W3025720477 hasRelatedWork W2961042511 @default.
• W3025720477 hasRelatedWork W3007976935 @default.
• W3025720477 hasRelatedWork W3025720477 @default.
• W3025720477 hasRelatedWork W3033877262 @default.
• W3025720477 hasRelatedWork W3118442307 @default.
• W3025720477 hasRelatedWork W3177447256 @default.
• W3025720477 hasRelatedWork W4284700853 @default.
• W3025720477 hasVolume "23" @default.
• W3025720477 isParatext "false" @default.
• W3025720477 isRetracted "false" @default.
• W3025720477 magId "3025720477" @default.
• W3025720477 workType "article" @default.